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Abstract
Background—Inherited genetic variations offer a possible explanation for the observed 
peculiarities of stroke in sub – Saharan African populations. Interleukin–6 polymorphisms have 
been previously associated with ischemic stroke in some non-African populations.
Aim—Herein we investigated, for the first time, the association of genetic polymorphisms of IL-6 
and CDKN2A- CDKN2B and other genes with ischemic stroke among indigenous West African 
participants in the Stroke Investigative Research and Education Network (SIREN) Study.
Methods—Twenty-three previously identified single nucleotide polymorphisms (SNPs) in 14 
genes of relevance to the neurobiology of ischemic stroke were investigated. Logistic regression 
models adjusting for known cardiovascular disease risk factors were constructed to assess the 
associations of the 24 SNPs in rigorously phenotyped cases (N=429) of ischemic stroke (Men = 
198; Women = 231) and stroke– free (N=483) controls (Men = 236; Women = 247).
Results—Interleukin-6 (IL6) rs1800796 (C minor allele; frequency: West Africans = 8.6%) was 
significantly associated with ischemic stroke in men (OR = 2.006, 95% CI = [1.065, 3.777], p = 
0.031) with hypertension in the model but not in women. In addition, rs2383207 in CDKN2A/
CDKN2B (minor allele A with frequency: West Africans = 1.7%) was also associated with 
ischemic stroke in men (OR = 2.550, 95% CI = [1.027, 6.331], p = 0.044) with primary covariates 
in the model, but not in women. Polymorphisms in other genes did not show significant 
association with ischemic stroke.
Conclusion—Polymorphisms rs1800796 in IL6 gene and rs2383207 in CDKN2A/CDKN2B 
gene have significant associations with ischemic stroke in indigenous West African men. 
CDKN2A/CDKN2B SNP rs2383207 is independently associated with ischemic stroke in 
indigenous West African men. Further research should focus on the contributions of inflammatory 
genes and other genetic polymorphisms, as well as the influence of sex on the neurobiology of 
stroke in people of African ancestry.
Keywords
Interleukin-6; Candidate Gene; Stroke; West Africa
INTRODUCTION
Stroke is the clinical culmination of complex biological processes and interacting pathways 
that involve non–genetic and genetic factors.1 In fact, the burden of stroke has significant 
race-ethnic and geographic disparities, with individuals of African ancestry being at higher 
risk, and experiencing poorer outcomes than most other racial groups in the world.2–5 
Inherited genetic variations offer a possible explanation for the observed peculiarities of 
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stroke in sub – Saharan African populations, as well as the proportion of risk that remains 
unexplained by traditional and emerging risk factors alone.6
Through multiple approaches including candidate gene, linkage studies, genome wide 
association studies (GWAS) and whole exome sequencing, multiple susceptibility loci for 
stroke have now been identified especially in populations of European ancestry, with fewer 
studies among African Americans, and very little data on indigenous sub – Saharan 
Africans.6 Thus, the Stroke Investigative Research and Education Network (SIREN) study is 
exploring genetic factors in stroke among West Africans using multi – level approaches.7 We 
herein report the findings of a candidate gene study using genotype and phenotype data from 
ischemic stroke and stroke – free controls recruited into the SIREN Study. We investigated 
the association and effect sizes of 23 selected SNPs with the occurrence of ischemic stroke 
among indigenous West Africans.
METHODS
Study Population, Patient Enrollment and Data Acquisition
The rationale and design of the SIREN study has been described elsewhere.7 Essentially, the 
SIREN study is a multi-center case-control study involving several sites in Nigeria and 
Ghana which was initiated in August 2014 with an initial recruitment target of 3000 cases 
and 3000 controls. The ethnographic characteristics of the study population are described in 
detail in supplementary table 1. The ethnic groups include the Yoruba (Ibadan and Abeokuta 
sites in southern Nigeria), the Hausa (Kano and Zaria in Northern Nigeria), the Akan, Ewe 
and Ga/Adangbe (Accra and Kumasi, Southern and Northern Ghana).10 Ethical approval 
was obtained for all study sites and informed consent was obtained from all subjects. Cases 
included consecutively recruited consenting adults (aged 18 years or older) with first clinical 
stroke within 8 days of current symptom onset or ‘last seen without deficit’ with 
confirmatory cranial CT or MRI scan performed within 10 days of symptom onset. We 
excluded individuals with stroke mimics, primary subarachnoid hemorrhage and previous 
strokes which were not ascertained by neuroimaging. Stroke-free status of controls recruited 
for the SIREN was ascertained using a locally-validated version of the Questionnaire for 
Verifying Stroke-Free Status (QVSFS) with a modification to include pictograms of stroke 
symptoms with improved sensitivity and specificity.8,9
We collected basic demographic and lifestyle data including ethnicity and native language of 
the subjects and their parents, socioeconomic status, dietary patterns, routine physical 
activity, stress, depression, cigarette smoking, and alcohol use as well as cardiovascular and 
anthropometric measurements using standard techniques. A detailed neurologic evaluation 
was conducted to assess neurologic deficits and determine stroke severity using the National 
Institute of Health Stroke Severity Score. Blood samples were collected from cases and 
controls at baseline for measuring fasting lipid profile, blood glucose and HbA1c. Stroke 
diagnosis and phenotyping was undertaken using the ACCESS software [Patent No: 
NG/PT/NC/2016/2007] based on clinical evaluation and brain neuroimaging (brain CT or 
MRI).
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Description of Covariates
Hypertension, diabetes mellitus, dyslipidemia, and central adiposity were used as 
dichotomous covariates in the models and are described in Table 1. Dyslipidemia was 
defined in accordance with the recommendations of the US National Cholesterol Education 
Program10.
Selection of stroke candidate genes and SNPs
Through an extensive literature review 24 single nucleotide polymorphisms (SNPs) from 14 
candidate genes with published and /or suspected association with ischemic stroke risk were 
selected for genotyping (Table 2). Majority of these were SNPs already associated with 
ischemic strokes and validated in at least more than one cohort. However, selection of the 
APOL1 G1 [rs73885319 and rs60910145] was largely exploratory based on recent data 
suggesting increasing role of the APOL1 in cardiovascular disease in people of African 
ancestry.14
Genotyping and Quality Control Method
Genomic DNA was extracted from whole blood with Gentra Systems PUREGENE DNA 
purification kit (Qiagen Group) according to manufacturers’ protocol. Genotyping was 
carried out on genomic DNA from 506 stroke cases and 506 stroke free controls randomly 
selected from among the entire cohort of recruited subjects as described above. The 
genotyping was performed at Northwest Genomics Center in Washington Seattle, USA, 
using an ABI TaqMan SNP genotyping assays by Design (Applied Systems) under 
conditions recommended by the manufacturer. Probe and primer sequences for each assay 
are available on request. The assays were originally selected for 24 published vascular 
disease-associated single nucleotide polymorphisms (SNPs) (Table 2) and included 3 SNPs 
on pro-inflammatory genes (IL6 and CD14) genes which have been previously reported to 
be associated with ischemic stroke in African Americans. Standard quality control 
procedures were applied to the genotype data using all SNPs on the chip. We also genotyped 
sickle cell SNP rs334 to control for confounding due to sickle cell trait.
Excluded subjects
After rigorous quality control of genotype data, individuals with sex discordance between 
reported and observed from genetic data and 44 cases with hemorrhagic stroke were 
excluded. There were 4 samples with sickle cell anemia and 5 samples with missing 
genotype for rs334 (Supplementary Table 2). After excluding participants whose genotype 
data did not pass quality control, the study sample consisted of 912 subjects (429 ischemic 
stroke cases and 483 stroke – free controls).
Power calculation
With the 429 cases and 483 controls, we can observe minimum OR of 2.8 with correction 
for multiple testing (α=0.05/23=0.002) with allele frequency as low as 0.02. However, we 
can observe minimum OR of 2.06 with correction for multiple testing (α=0.05/23=0.002) 
with allele frequency as low as 0.05.
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Association Methods
All statistical analyses were performed using PLINK1.9. We compared proportions or means 
by two-sided t-tests and for stratified samples with respect to sex we used χ2 tests or 
Fisher’s exact test if the cell size was less than 5. All SNPs were in Hardy-Weinberg 
equilibrium except rs60910145 in APOL1 gene (p= 2.3 × 10−6) (Supplementary Table 3). To 
test for associations between ischemic stroke status and each single SNP, we fitted logistic 
regression models in which each SNP was modeled as a predictor variable whose values 
were equal to the number of copies of the minor allele (0, 1, 2) (i.e., additive mode of 
inheritance). The primary fitted model included age, sex ethnicity and rs334 (sickle cell 
status) as covariates. Majority of the individuals were from Akan, Yoruba, and Hausa. The 
other ethnicities were combined as one to avoid small sample size issues within each 
categories. Ethnicity was modeled as categorical variable. Recruitment site was not 
significant in any of our analysis due to strict protocol followed at each site. Therefore, we 
did not use site in the model. Furthermore, we also performed sex stratified logistic 
regression because of reported gender disparities in stroke prevalence, incidence, severity 
and outcomes.5,15–17 In the primary sensitivity analysis model, we added history of 
hypertension, while in the secondary model we further added dichotomous variables for 
diabetes, dyslipidemia, and waist-hip as predictors defined in table 1 step-wisely to ascertain 
whether these covariates had independent effects. The statistical models are described below.
Analyzed Models
• Model 1 (Primary Model): SNP + Age + Sickle-Cell Status + Ethnicity
• Model 2 (Model 1 + Hypertension): SNP + Age + Sickle-Cell Status + 
Ethnicity + Hypertension
• Model 3 (Model 2 + Diabetes): SNP + Age + Sickle-Cell Status + Ethnicity + 
Hypertension + Diabetes
• Model 4 (Model 3 + Dyslipidemia): SNP + Age + Sickle-Cell Status + 
Ethnicity + Hypertension + Diabetes + Dyslipidemia
• Model 5 (Model 4 + waist-hip-ratio): SNP + Age + Sickle-Cell-Status + 
Ethnicity + Hypertension + Diabetes + Dyslipidemia + waist-hip-ratio
In addition, we ran exact logistic regression analysis to ensure that our results were not 
affected by small or zero cell counts for covariates used in the sensitivity analysis.
RESULTS
Subject Characteristics and Distribution of Covariates
The demographic and risk factor characteristics by case-control status are described in Table 
3. The mean age of the subjects with ischemic stroke was 61.34 (±12.83) years while the 
mean age of stroke – free control subjects was 60.26 (± 12.56) years (p =0.2001). Cases 
were significantly more likely than controls to have a history of hypertension (90% vs. 42%) 
(p <0.0001), diabetes (39% vs 14%) (p <0.0001), dyslipidemia (87% vs. 58%) (p <0.0001) 
and abnormal waist – hip ratio (25% vs. 11%) (p <0.0001), whereas there were no 
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statistically significant differences between cases and controls with respect to age (p=0.233), 
sex (p=0.4528), ethnicity (p: 0.0830 – 0.8871), and recruitment site (p: 0.192 – 1.000). The 
ischemic stroke subtypes are as shown in Table 3. Hypertension is often undiagnosed in the 
population, and so duration as well as family history may not be accurate. However, known 
family history of hypertension in parents or siblings was absent in 300 cases and 394 
controls. Smoking and atrial fibrillation were not important risk factors in this population. 
The percentage of those with atrial fibrillation was <5% while smoking was also rare. Waist 
– hip ratio was included as a measure of obesity rather than BMI (Table 3).
Genotyping
We genotyped 23 candidate SNPs in 14 genes that have been previously associated with 
stroke risk (Table 2), including APOL1 G1 SNP variants and HBB SNP rs334 (a surrogate 
SNP for sickle cell anemia). Genotypic distribution of rs334 is provided in Supplementary 
Table 2. SNP rs74475935 in candidate gene ABCC1 was missing in all individuals due to 
failed assay and SNP rs60910145 in APOL1 was not in HWE (p=2.3E-6). Details of the 
minor allele and its frequency in both cases and controls, genotypic distribution of each SNP 
in controls, HWE p-values, gene names reported by ANNOVAR, SNP function, 
comparisons of allele frequencies with 1000 Genome project populations, and functional 
score CADD are described in Supplementary Table 3.
Association
We did not observe any significant association with stroke when case-control analysis was 
done using sex and other covariates in the primary logistic regression model as described in 
the methods section. However, when we analyzed case-control sex-stratified data, we 
observed rs1800796 in IL-6 (minor allele C with frequency=8.6% in controls and 9.4% in 
cases (OR=1.645; 95% CI: 0.971–2.789; p-value=0.065) and rs2383207 in CDKN2A/
CDKN2B (minor allele A with frequency=1.7% in controls and 2.7% in cases) was 
significant with p-value=0.044 (OR=2.550; 95% CI: 1.027–6.331) with only primary 
covariates in the model. The effect sizes and p-values for both SNPs are detailed in Table 4 
including sensitivity analyses. In the sensitivity analysis, rs1800796 in IL-6 was significant 
with p-value=0.031 (OR=2.006; 95% CI: 1.065–3.777) with hypertension in the model; p-
value=0.038 (OR=1.957; 95% CI: 1.038–3.690) with the addition of diabetes to the model; 
p-value=0.051 (OR=1.886; 95% CI: 0.998–3.564) with further addition of dyslipidemia to 
the model; and p-value (p=0.132) was not significant when we finally added waist-hip-ratio. 
Similarly, rs2383207 in CDKN2A/CDKN2B was not significant with hypertension, 
diabetes, and dyslipidemia in the model. However, the rs2383207 in CDKN2A/CDKN2B 
became significant when we added waist-hip-ratio to the model. The results for male only 
analyses for all SNPs are detailed in the Supplementary Table 4 and the results for non-
genetic covariates are given in the Supplementary Tables 5 and 6 for SNPs rs1800796 and 
rs2383207, respectively. Furthermore the significance of IL6 SNP was confirmed using 
exact logistic regression with 20K burn in and 100K interactions with the primary model as 
well as when the models included other covariates (Supplementary Table 7). The association 
of rs2383207 in CDKN2B-AS1 was not significant with the primary model, inclusion of 
hypertension and diabetes. However, rs2383207 was significant with p-value 0.044 with 
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inclusion of dyslipidemia in the model. In supplementary table 8, we compare the effect size 
and direction for IL-6 SNP rs1800796 with previous reports.
In the step-wise analyses, ethnicity, hypertension, dyslipidemia, diabetes, and waist-hip ratio 
risk were significant irrespective of SNP in the model (Supplementary Table 5). Specifically, 
in the final model with all covariates and rs1800796 in the model, ethnicity (Akan: p=0.004; 
Hausa: p=0.004; and other: p=0.733), hypertension (3.93E-15), diabetes (p=0.039), 
dyslipidemia (1.77E-05), and waist-hip ratio risk (p=0.004). Also in the final model with all 
covariates and rs2383207 in the model ethnicity (Akan: p=0.006; Hausa: p=0.005; and other: 
p=0.635), hypertension (p=8.17E-15), diabetes (p=0.038), dyslipidemia (p=6.23E-06), and 
waist-hip ratio risk (p=0.001). Thus, it implies that ethnicity, hypertension, dyslipidemia, 
diabetes, and waist-hip ratio risk were independent predictors of ischemic stroke. We did not 
include smoking and atrial fibrillation in the regression models because they were not 
important stroke risk factors in this population. The percentage of those with atrial 
fibrillation was <5% and smoking was also rare (Table 3). We also did not include family 
history and duration of hypertension in the regression analysis model because they were 
largely presumed. Note that Yoruba sample was the largest sample, so the program used 
Yoruba sample as a reference sample in the analysis.
To see whether the difference of SNP-stroke association between sex-stratified analyses was 
significant or it was due to small sample size, we included SNP by sex interaction in the 
final model without sex-stratified sample and observed the following results: The interaction 
p-values for sex × rs1800796 and sex × rs2383207 were 0.08 and 0.06 respectively showing 
marginal significance. The female − specific sex-stratified logistic regression analysis results 
are shown in Supplementary Table 8.
DISCUSSION
In this first ever case – control study of genetic polymorphisms associated with ischemic 
stroke among West Africans, we found that the polymorphisms rs1800796 in the 
interleukin–6 gene and rs2383207 in the CDKN2A/CDKN2B gene were associated with 
nominal significance with the occurrence of ischemic stroke in men. This also represents the 
first report of the analysis of association of any inflammatory genetic polymorphism 
(rs1800796) and cardiovascular polymorphism (rs2383207) with stroke occurrence in sub– 
Saharan Africa.
The finding of the significant association between IL-6 rs1800796 and ischemic stroke is 
congruent with previous reports of similar association of IL-6 polymorphisms with ischemic 
stroke among African American21, American Caucasian22 Japanese23 northern Chinese 
Han24,25 and northern Indian26 populations. The odds ratio reported in this study lies within 
the range of 1.40 – 2.50 previously reported in other studies21–26, noting that differences in 
effect size may be due to differences in sample size and the sex – stratified analysis 
undertaken in the present study (Table 5). The IL-6 promoter gene polymorphisms G174C 
(rs1800795),C572G (rs1800796) and IL6 rs2069832 have been particularly associated with 
the occurrence of ischemic stroke21,27 while IL6 rs2069830 was protective against ischemic 
stroke among African American non – smokers in a biracial study.21 While previous studies 
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did not conduct stratified analysis to explore the effect of sex, the significant association 
between IL-6 rs1800796 gene and rs2383207 CDKN2A/CDKN2B and ischemic stroke in 
men only agrees with a recent study of Li et al. (2015) using integrated microarray datasets, 
in which IL-6 gene expression was significantly upregulated in male patients but down – 
regulated in female patients.28 This evidence provides a possible genetic basis for gender 
disparity in the epidemiology of stroke5,15,16,29,30.
The human interleukin – 6 (IL-6) gene is located on chromosome 7p21 and consists of 5 
exons and 4 introns. The promoter polymorphisms of IL-6 regulate the circulating plasma 
level of this pleiotropic cytokine which plays critical roles in the acute inflammatory 
response and regulation of acute phase proteins such as C – reactive protein. It also 
contributes to the inflammatory response by triggering endothelial dysfunction and 
activating the coagulation – fibrinolysis system.22,31 Studies have demonstrated association 
of serum levels of biomarkers of inflammation such as Interleukin – 6, C – reactive protein 
and fibrinogen with such conditions as stroke, myocardial infarction and cardiovascular 
deaths.22 Serum and cerebrospinal fluid IL–6 levels have also been associated with greater 
stroke severity, larger infarct volume and worse functional outcomes as well as carotid artery 
intima – media thickness, other vascular brain diseases (white matter hyperintensities and 
lacunar infarction), vascular cognitive impairment and Alzheimer’s disease.27,32–34 Fine 
particulate matter air pollution has been associated with elevated plasma levels of IL-6.35 
The recently published report on the Global Burden of Disease 2013 (GBD 2013) study 
demonstrated the significant contribution of household air pollution to the risk of stroke 
especially in low and middle income countries, the largest risk been reported from the West 
African sub – region.8 The significant association of IL- 6 polymorphism and stroke in this 
study strengthens the putative contribution of air pollution (which triggers chronic 
inflammation and atherosclerosis) to stroke risk in the West African sub- region, and this 
warrants further detailed investigation.
The CDKN2A/CDKN2B gene is located in the intron of cyclin – dependent kinase inhibitor 
2B anti sense RNA 136 and associated with type 2 DM and cerebral infarction (Table 2). It 
was also implicated in large artery stroke in the COMPASS Consortium37. It became 
significant in the current study when waist –hip-ratio was added to the sensitivity analysis in 
the presence of ethnicity, hypertension, type 2 DM, and dyslipidemia. This might suggest a 
possible confounding effect although waist-hip ratio was an independent predictor of stroke.
The association of both IL- 6 and CDKN2A/CDKN2B genes with ischemic stroke have been 
confirmed by the COMPASS consortium and other previous studies although there were no 
specific data from stratified analysis based on gender and obesity.21–26 However, IL- 6 as a 
multifunctional cytokine plays a key role in chronic inflammation and SNP rs1800796 is 
associated with susceptibility to several diseases including breast cancer38,39, osteoarthritis40 
and membranous glomerulopathy41. Furthermore, the sex disparity related to IL-6 
polymorphisms is not limited to stroke but also influences susceptibility to other diseases. 
One of such studies conducted in China suggested that rs1800796 polymorphism of the IL-6 
gene was associated with susceptibility to HBV-related hepatocellular carcinoma in a male 
Chinese Han population.42,43 Our rigorous association analysis which adequately controlled 
for confounders and duly considered LD structure did not establish an association of APOE 
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alleles with ischemic stroke in our cohort contrary to an earlier finding in a small Zambian 
stroke cohort.44 The lack of association of the HBB rs334 and stroke in this study suggests 
that the sickle cell carrier status may not be a significant risk factor for stroke in the 
population under study.
This study has limitations. We only evaluated a limited number of SNPs identified in prior 
stroke genetic studies and were unable to study rare variants due to limited sample size and 
thus lack of adequate power to observe small effect loci with multiple test correction 
although our study had adequate power to detect larger effect loci. We would have needed 
984 matched case-control pairs to observe an OR of 1.5 with minor allele frequency of 8.6% 
(~0.09) similar to IL-6 rs1800796 while 3960 matched case-control pairs would have been 
needed to observe an OR of 1.5 with minor allele frequency of 1.7% (~0.02) similar to 
CDKN2A/CDKN2B rs2383207. Supplementary Table 9 shows sample size calculations 
corresponding to an OR less than or equal to 1.5 and minor allele frequency varying from 
0.01 to 0.2 to further illustrate the sample size limitation of our study to replicate the 
associated candidate SNPs. Thirdly, we did not evaluate relationship with plasma protein 
activity. Finally, we did not adjust for population structure due to unavailability of ancestry 
informative markers in this current study. This is because we acknowledge that multi – 
ethnicity raises the possibility that certain findings may result from the confounding effects 
of genetic differences among populations. However, multi – ethnicity of the sample could 
boost our understanding of the scope and generality of any findings, because pan-ethnic 
replicability of association between a candidate SNP and trait outcome provides support for 
a causal relationship.
Another advantage of having an ethnically diverse sample is that patterns of linkage 
disequilibrium may differ ethnically, helping to resolve causal from non-causal relationships. 
While populations with high linkage disequilibrium may be useful for initial detection of 
SNP associations, several different SNPs may be in strong or complete disequilibrium. 
Populations with lower levels of disequilibrium can help resolve which SNP effect is 
primary. Africans appear to have the lowest levels of linkage disequilibrium and hence are 
likely to be most useful for such analyses.45 Certain SNPs have been previously detected in 
stroke patients in other populations.46–48 Therefore, searching for such among diverse ethnic 
groups in Africans and African Americans using the candidate gene approach is a good 
starting point for exploring stroke genomics in this unique population.49,50
Our future work will examine our current findings and all current GWAS hits with greater 
power and breadth within the context of a genome wide association studies on the entire 
SIREN cohort of 6000 subjects, whole genome sequencing in an enriched sub-cohort of 
familial small vessel disease (lacunar stroke), external validation of findings in other genetic 
stroke cohorts and consortia, pathway – based analyses and functional genomic studies to 
facilitate translational applications.
CONCLUSIONS/IMPLICATIONS
We observed that the polymorphisms rs1800796 in the interleukin-6 gene and rs2383207 in 
CDKN2A/CDKN2B were associated with ischemic stroke in men with nominal significance 
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but not women in West Africa. Certainly, further research is needed to more clearly 
understand the contributions of sex, other inflammatory genes and other genetic 
polymorphisms (including angiogenesis and obesity genes) to the neurobiology of stroke in 
people of African ancestry.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Polymorphisms rs1800796 in IL6 gene and rs2383207 in CDKN2A/
CDKN2B gene have significant associations with ischemic stroke in 
indigenous West African men.
• CDKN2A/CDKN2B SNP rs2383207 is independently associated with 
ischemic stroke in indigenous West African men.
• Abnormal waist-hip-ratio may be an important modifier interacting with 
CDKN2A/CDKN2B gene to result in cerebral infarction among indigenous 
West African men.
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Table 1
Definition of dichotomous risk factors for stroke used as covariates in the statistical analysis.
Risk factor Definition: If any of the outcomes within each category are met then risk is considered as Yes otherwise No.
Hypertension • Presence of sustained systolic BP≥140 mmHg or diastolic BP≥90 mmHg after onset of stroke
• A history of hypertension
• Taking antihypertensive medications before stroke.13
Diabetes Mellitus • Previous history of diabetes mellitus
• Use of medications for diabetes mellitus,
• Fasting glucose levels≥126 mg/dl and/or HBA1c≥6.5%.10,13
Dyslipidemia • High fasting serum total cholesterol ≥200 mg/dl
• High Density lipoprotein (HDL)≤40 mg/dl10
• Low Density Lipoprotein (LDL)≥130
• Triglyceride(Trig) ≥ 150 mg/dl
• History of use of statins before stroke were considered as risk to
• stroke.
Central Adiposity • A waist–hip–ratio of ≥ 0.90 (men) and ≥ 0.85 (women)10
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Table 3
Characteristics of the SIREN case-control samples after QC.
Variable Status/Values A : Controls
(N=483)
B: Cases
(N=429)
P-value comparing
A and B
Baseline Age (mean ± SD) 60.26 (± 12.56) 61.34 (± 12.83) 0.2001
SEX (M/F) 236/247 198/231 0.4528
Sickle-Cell Status 100/383 85/344 0.8016
Hypertension (Risk / N-Risk) 201/281 378/44 < 0.0001
Diabetes 67/415 166/260 < 0.0001
Dyslipidemia (Risk / No-Risk) 282/201 370/55 < 0.0001
Waist-Hip Ratio (Risk / No-Risk) 344/115 332/40 < 0.0001
Atrial Fibrillation (Yes/No) 0/483 13/417 <0.0001
Tobacco use (Yes/No) 1/476 14/410 0.0003
Ethnicity Akan 68/80 39/74 0.0830
Yoruba 119/109 117/112 0.8871
Ga/Adangbe/Igbo/Gonja/Bono/Busanga 25/30 27/18 0.2123
Hausa 24/27 14/27 0.2996
Family history of hypertension Both Parents (0/1/2) 413/45/18 327/72/26 0.0006
Both Parents and Sibling (0/1/2/3) 394/54/23/5 300/70/40/15 <0.0001
TOAST Status (M/F) TOAST-Small NA 72/82
TOAST-Large NA 67/90
TOAST-Cardio NA 28/23
TOAST – Undetermined NA 31/36
Family History of hypertension (No-member-endorsed / 1-member-endorsed / 2-members-endorsed / 3-members-endorsed) Tobacco use was 
classified as Yes=current user and stopped after stroke occurred.
No=formally use or never used. NA: Not applicable
J Neurol Sci. Author manuscript; available in PMC 2018 August 15.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Akinyemi et al. Page 18
Ta
b
le
 4
Si
gn
if
ic
an
t S
N
P 
as
so
ci
at
io
ns
 a
nd
 c
or
re
sp
on
di
ng
 o
dd
s 
ra
tio
 w
ith
 C
on
fi
de
nc
e 
In
te
rv
al
 (
C
I)
 f
or
 s
ex
-s
tr
at
if
ie
d 
an
al
ys
is
 o
f 
M
al
es
 o
nl
y.
SN
P
G
en
e 
N
am
e
M
in
or
 A
lle
le
M
od
el
O
dd
s 
R
at
io
 (
O
R
)
L
95
 O
R
U
95
 O
R
P
-v
al
ue
rs
18
00
79
6
IL
6
C
M
od
el
 1
1.
64
5
0.
97
1
2.
78
9
0.
06
5
M
od
el
 2
2.
00
6
1.
06
5
3.
77
7
0.
03
1
M
od
el
 3
1.
95
7
1.
03
8
3.
69
0
0.
03
8
M
od
el
 4
1.
88
6
0.
99
8
3.
56
4
0.
05
1
M
od
el
 5
1.
65
4
0.
85
9
3.
18
4
0.
13
2
rs
23
83
20
7
C
D
K
N
2A
/C
D
K
N
2B
A
M
od
el
 1
2.
55
0
1.
02
7
6.
33
1
0.
04
4
M
od
el
 2
2.
51
3
0.
77
8
8.
11
6
0.
12
3
M
od
el
 3
2.
51
9
0.
77
3
8.
21
3
0.
12
6
M
od
el
 4
2.
85
2
0.
90
6
8.
97
9
0.
07
3
M
od
el
 5
5.
04
7
1.
44
6
17
.6
10
0.
01
1
J Neurol Sci. Author manuscript; available in PMC 2018 August 15.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Akinyemi et al. Page 19
Ta
b
le
 5
C
om
pa
ra
tiv
e 
sa
m
pl
e 
si
ze
, o
dd
s 
ra
tio
 a
nd
 p
 –
 v
al
ue
s 
of
 s
tu
di
es
 r
ep
or
tin
g 
as
so
ci
at
io
n 
of
 I
L
-6
 w
ith
 is
ch
em
ic
 s
tr
ok
e.
A
ut
ho
rs
/S
N
P
Se
x-
st
ra
ti
fi
ed
 a
na
ly
si
s
R
is
k 
A
lle
le
Sa
m
pl
e 
si
ze
O
dd
s 
R
at
io
 (
95
%
C
I)
p-
va
lu
e
Y
am
ad
a 
et
 a
l. 
(2
00
6)
rs
18
00
79
6
N
o
C
63
6 
is
ch
em
ic
 s
tr
ok
e 
vs
 2
01
0 
co
nt
ro
ls
1.
40
 (
1.
15
 –
 1
.7
0)
<
0.
00
1
Fo
rn
ag
e 
et
 a
l. 
(2
00
8)
rs
18
00
79
6
N
o
C
30
73
 w
hi
te
s 
vs
 5
71
 b
la
ck
s
1.
57
 (
1.
15
 –
 2
.1
4)
0.
00
1
C
ol
e 
et
 a
l. 
(2
00
8)
rs
20
69
83
2
N
o 
(s
ub
je
ct
s 
w
er
e 
al
l w
om
en
)
C
22
4 
is
ch
em
ic
 s
tr
ok
e 
vs
 2
11
 c
on
tr
ol
s 
(w
om
en
 o
nl
y)
2.
5 
(1
.0
 –
 6
.5
0)
0.
05
0
To
ng
 e
t a
l. 
(2
01
0)
rs
18
00
79
6
N
o
G
74
8 
is
ch
em
ic
 s
tr
ok
e 
vs
 7
48
 c
on
tr
ol
s
1.
45
 (
1.
13
 –
 1
.8
6)
0.
00
4
W
an
g 
et
 a
l. 
(2
01
4)
rs
18
00
79
6
N
o
G
22
7 
is
ch
em
ic
 s
tr
ok
e 
vs
 6
22
 c
on
tr
ol
s
1.
55
 (
1.
01
 –
 2
.3
7)
0.
04
3
T
hi
s 
St
ud
y
rs
18
00
79
6
Y
es
C
42
8 
is
ch
em
ic
 s
tr
ok
e 
vs
 4
83
 c
on
tr
ol
s
2.
01
 (
1.
06
 –
 3
.7
8)
 m
al
es
 o
nl
y
0.
03
1
J Neurol Sci. Author manuscript; available in PMC 2018 August 15.
